Growth Spurt: Endo Pharmaceuticals - ' Pain' (
Page 5 of 5 )
-Free in 2002">
Endo Pharmaceuticals: Pain-Free in 2002
Percocet manufacturer Endo Pharmaceuticals worried it might grow so fast, it installed SAP R/3 as its enterprise planning software, from its inception as an offshoot of a Dupont-Merck joint venture. Last year proved the case: The company raised its "guidance" on annual sales for the year three times. And its final estimate was still too low.
Sales of Percocet and Lidoderm pain drugs spur first revision of projected revenue.
Migration begins to fourth version of SAP customer management software.
Cash flow doubles; net loss reduced by 45%.
Still on tap: Linking Futurecast sales-forecasting software to SAP.
Final sales for the year: $399M
Projection raised one last time
$380M
Projection raised again, to $350M
$285.5M
Projection raised to $300M at start of Q2...
$174.9M
$400M
Sales projected
for full year:
$280M
300
200
100
$67M
0
BASELINE Company's guidance to market on expected sales for the year, before each quarter started.
ACTUAL Endo's sales, year to date.
Source: ENDO PHARMACEUTICALS
Projects: Enterprise Planning 
